lapatinib has been researched along with tetracycline in 5 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (tetracycline) | Trials (tetracycline) | Recent Studies (post-2010) (tetracycline) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 21,524 | 977 | 3,656 |
Protein | Taxonomy | lapatinib (IC50) | tetracycline (IC50) |
---|---|---|---|
90-kda heat shock protein beta HSP90 beta, partial | Homo sapiens (human) | 22.4474 | |
heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | 22.4474 | |
tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | 8.33 | |
30S ribosomal protein S6 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S7 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L15 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L10 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L11 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L7/L12 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L19 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L1 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L20 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L27 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L28 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L29 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L31 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L31 type B | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L32 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L33 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L34 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L35 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L36 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S10 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S11 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S12 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S13 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S16 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S18 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S19 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S20 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S2 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S3 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S4 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S5 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S8 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S9 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L13 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L14 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L16 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L23 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S15 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L17 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L21 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L30 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L6 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S14 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S17 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S1 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L18 | Escherichia coli K-12 | 4.58 | |
Alpha-synuclein | Homo sapiens (human) | 6.06 | |
50S ribosomal protein L2 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L3 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L24 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L4 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L22 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L5 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S21 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L25 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L36 2 | Escherichia coli K-12 | 4.58 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
1 review(s) available for lapatinib and tetracycline
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for lapatinib and tetracycline
Article | Year |
---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |